<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00588120</url>
  </required_header>
  <id_info>
    <org_study_id>1026-98</org_study_id>
    <secondary_id>RFA-OD-08-001</secondary_id>
    <secondary_id>1U54DK083908-01</secondary_id>
    <nct_id>NCT00588120</nct_id>
  </id_info>
  <brief_title>Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria</brief_title>
  <official_title>Investigations Into the Genotype and Phenotype of Unclassified Hyperoxaluria: Enteric Oxalate Absorption Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxalosis and Hyperoxaluria Foundation (OHF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about a condition called 'unclassified
      hyperoxaluria'. People with this condition have large amounts of oxalate in their urine,
      which can cause kidney stones and kidney failure. We do not know what causes the high level
      of oxalate in the urine. In this study, we will evaluate absorption of a test dose of oxalate
      taken orally by measuring the amount of the test dose that is eliminated in the urine. We
      will compare the results of affected patients to healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants' oxalate intake and output will be monitored and assessed over a 24 hour period.
      Participants will ingest a prescribed oxalate dose and urine oxalate will be monitored for
      the 24 hour study period.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 1998</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine oxalate measured following absorption of oral oxalate dose</measure>
    <time_frame>2 years</time_frame>
    <description>Subjects with hyperoxaluria will be given an oral test dose of oxalate, with measurement of urine oxalate excretion over the next 24 hours.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Enteric Hyperoxaluria</condition>
  <condition>Hyperoxaluria</condition>
  <arm_group>
    <arm_group_label>C-13 labeled oxalate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperoxaluric patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-13 labeled oxalate</intervention_name>
    <description>A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.
Take one capsule by mouth for one day.</description>
    <arm_group_label>C-13 labeled oxalate</arm_group_label>
    <other_name>oxalate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal to or greater than 4 years (patient must be able to void on request).

          -  Have good health.

        Exclusion Criteria:

          -  Any prior history of renal disease, or hypertension

          -  ALL subjects (controls and affected patients) will be asked to discontinue any
             diuretics, calcium supplements, H2 blockers, proton pump inhibitors or
             gastrointestinal motility agents for approximately one week prior to initiation of the
             study.

          -  Subjects with GFR &lt; 50 cc/min will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Milliner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2008</study_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John Lieske</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hyperoxaluria</keyword>
  <keyword>Unknown Hyperoxaluria</keyword>
  <keyword>Enteric Hyperoxaluria</keyword>
  <keyword>Oxaluric</keyword>
  <keyword>High Oxalate</keyword>
  <keyword>Oxalate</keyword>
  <keyword>C13</keyword>
  <keyword>Oxalate Diet</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

